• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    2/9/22 3:43:35 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DARE alert in real time by email
    SC 13G/A 1 tv0711-darebioscienceinc_a.htm SCHEDULE 13G/A darebioscienceinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Dare Bioscience Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  23666P101

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  23666P101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    8,780

    7.  SOLE DISPOSITIVE POWER

    3,030,136

    8.  SHARED DISPOSITIVE POWER

    25,917

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,056,053

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    3.99%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    13G

    CUSIP No.:  23666P101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund - 23-2671505

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Delaware

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    2,082,157

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    0

    8.  SHARED DISPOSITIVE POWER

    0

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,082,157

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.72%

    12.  TYPE OF REPORTING PERSON

    IV

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Dare Bioscience Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3655 Nobel Drive, Suite 260
    San Diego, CA 92122

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund - 23-2671505

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    The Vanguard Group
    Pennsylvania

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund
    Delaware

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    23666P101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  The Vanguard Group: An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). Vanguard Index Funds - Vanguard Total Stock Market Index Fund: Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    The Vanguard Group

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Chief Financial Officer and Acting Treasurer of the Vanguard Funds

    Get the next $DARE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DARE

    DatePrice TargetRatingAnalyst
    6/30/2021$9.00 → $11.00Buy
    Roth Capital
    More analyst ratings

    $DARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Dare Bioscience with a new price target

      Roth Capital reiterated coverage of Dare Bioscience with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      6/30/21 9:55:24 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Financials

    Live finance-specific insights

    See more
    • Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2025, to review its financial results for the quarter ended March 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 3461324. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.

      5/6/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

      Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Daré proprietary formulations to market as soon as practicable SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today reported financial results for the year

      3/31/25 4:01:00 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

      SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximate

      3/24/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2025, to review its financial results for the quarter ended March 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 3461324. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.

      5/6/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation

      Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path approach for its proprietary Sildenafil Cream formulation and is targeting availability via prescription in Q4 2025 SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that Sabrina Martucci Johnson, the company's President and CEO, will provide a keynote address at the Fierce Pharma Engage summit for pharma and biotech industry leaders entitled Breaking Barriers, Building Acces

      4/23/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

      Daré unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from womenDaré is targeting availability of its proprietary Sildenafil Cream formulation via prescription in Q4 2025 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that Sabrina Martucci Johnson, the company's President and CEO, will present at the Jones Healthcare and Technology Innovation Conference on the company's expanded business strategy to integrate 503B c

      4/7/25 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

      Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/7/21 12:35:25 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Haring-Layton Mardee

      4 - Dare Bioscience, Inc. (0001401914) (Issuer)

      1/31/25 5:34:13 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chef Executive Officer Johnson Sabrina Martucci

      4 - Dare Bioscience, Inc. (0001401914) (Issuer)

      1/31/25 5:31:46 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Steele Robin Joan

      4 - Dare Bioscience, Inc. (0001401914) (Issuer)

      6/7/24 5:15:38 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Dare Bioscience Inc.

      DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)

      4/24/25 4:32:42 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Dare Bioscience Inc.

      DEF 14A - Dare Bioscience, Inc. (0001401914) (Filer)

      4/24/25 4:02:32 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dare Bioscience Inc. filed SEC Form 8-K: Other Events

      8-K - Dare Bioscience, Inc. (0001401914) (Filer)

      4/11/25 5:15:09 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Leadership Updates

    Live Leadership Updates

    See more
    • Daré Bioscience Announces Executive Team and Board of Directors Changes

      SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh

      1/26/24 4:30:00 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

      SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. "We are thrilled to add Dr. Ononye-Onyia to the Daré Board," said Sabrina Martucci Johnson, Daré's President and CEO. "Sophia has demonstrated the value of her leadership to global biopharmaceutical companies throughout her career. Her experience supporting commercialization of women's health products positions her to provide strategic guidance as our product candidates advance toward commercialization, and as we explore the variety of go-to-market partnering strategies

      4/19/21 8:00:00 AM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

      SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

      2/9/22 3:43:36 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

      SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

      2/9/22 3:43:35 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

      2/12/21 5:13:06 PM ET
      $DARE
      Biotechnology: Pharmaceutical Preparations
      Health Care